# Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

> **NCT03904862** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 21 (actual)

## Conditions studied

- Medulloblastoma, Childhood
- Medulloblastoma Recurrent
- Medulloblastoma

## Interventions

- **DRUG:** CX 4945

## Key facts

- **NCT ID:** NCT03904862
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-25
- **Primary completion:** 2025-08-11
- **Final completion:** 2025-08-11
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** The decision to permanently close PBTC-053 was made following communication from the NCI that the PBTC grant will not be extended beyond March 31, 2026.
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03904862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03904862, "Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03904862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*